{
  "kind": "treatment",
  "slug": "memantine-namenda",
  "type": "cognitive-enhancer",
  "name": "Memantine (Namenda)",
  "summary": "An NMDA receptor antagonist used to treat moderate-to-severe Alzheimer's disease.",
  "description": "Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that modulates the effects of glutamate, a neurotransmitter involved in learning and memory. Excessive activation of NMDA receptors is thought to contribute to neuronal damage in Alzheimer's disease. Memantine is approved for moderate-to-severe Alzheimer's disease and is sometimes used in combination with acetylcholinesterase inhibitors.",
  "category": "medications/cognitive-enhancers",
  "tags": [
    "nmda-antagonist",
    "alzheimers",
    "dementia"
  ],
  "metadata": {
    "drug_classes": [
      "NMDA Receptor Antagonist"
    ],
    "therapeutic_categories": [
      "Alzheimer's Disease",
      "Dementia"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Namenda"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "B",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Neurology",
      "Geriatrics"
    ],
    "fda_approval_year": 2003
  },
  "clinical_metadata": {
    "primary_indications": [
      "Dementia"
    ],
    "off_label_uses": [
      "Vascular dementia",
      "Parkinson's disease dementia"
    ],
    "contraindications": [
      "Hypersensitivity to memantine or any component of the formulation"
    ],
    "monitoring_required": [
      "Renal function in at-risk patients"
    ],
    "efficacy_rating": {
      "alzheimers": 3,
      "vascular_dementia": 2
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "memantine",
      "namenda",
      "nmda antagonist",
      "alzheimers"
    ],
    "synonyms": [
      "memantine hydrochloride"
    ],
    "common_misspellings": [
      "memantene",
      "mamantine"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Moderate-to-severe Alzheimer's disease",
        "Vascular dementia (off-label)"
      ]
    },
    {
      "type": "mechanism",
      "text": "Blocks NMDA receptor-associated ion channels in a voltage-dependent manner, reducing abnormal glutamatergic activity without disrupting normal neurotransmission."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "5 mg once daily",
        "titrate": "Increase by 5 mg/day in weekly intervals",
        "usual_range": "10 mg twice daily",
        "max": "20 mg/day"
      },
      "geriatric": "Same as adult; adjust for renal impairment",
      "hepatic_impairment": "No adjustment in mild/moderate; caution in severe",
      "renal_impairment": "Reduce dose to 5 mg twice daily if CrCl 5â€“29 mL/min"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Tablets: 5 mg, 10 mg",
        "Oral solution: 2 mg/mL",
        "Extended-release capsules: 7 mg, 14 mg, 21 mg, 28 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Benefits may be observed after several weeks; sustained with continued use."
    },
    {
      "type": "adverse_effects",
      "common": [
        "dizziness",
        "headache",
        "confusion",
        "constipation"
      ],
      "less_common": [
        "hallucinations",
        "hypertension",
        "fatigue"
      ],
      "serious": [
        "seizures",
        "heart failure exacerbation"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Use caution in patients with seizure disorders",
        "Monitor renal function in elderly or renally impaired"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Other NMDA antagonists (e.g., amantadine, ketamine)",
          "risk": "Additive side effects",
          "action": "Avoid or monitor"
        },
        {
          "with": "Carbonic anhydrase inhibitors or sodium bicarbonate",
          "risk": "Increased memantine levels",
          "action": "Monitor and adjust dose"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Cognitive function",
        "Renal function in at-risk patients",
        "Adverse effects"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Category B; use if benefits outweigh risks",
      "lactation": "Unknown excretion; caution advised",
      "pediatrics": "Not established",
      "geriatrics": "No major differences except for renal function considerations"
    },
    {
      "type": "tapering",
      "text": "May be stopped without tapering; abrupt discontinuation may lead to gradual decline in cognition."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Can be used alone or with cholinesterase inhibitors for added benefit",
        "Extended-release formulation allows once-daily dosing"
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Namenda Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "Alzheimer's Association Clinical Guidance",
          "url": "https://www.alz.org/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Memantine (Namenda): Alzheimer's Disease Treatment",
    "description": "Memantine is an NMDA receptor antagonist used to treat moderate-to-severe Alzheimer's disease, often in combination with cholinesterase inhibitors."
  }
}
